

Academy YOUR GMP/GDP Information Source

ICH Q9 / ICH Q10 **Training Courses**

Speakers:



Richard M. Bonner Formerly with Eli Lilly, UK



Dr Heinrich Prinz Apceth GmbH, Germany



Dr Bernd Renger Immediate Past Chair of the European QP Association; Renger Consulting, Germany



Dr Thomas Schneppe Bayer Pharma AG, Germany



Dr Helene Zuurmond Pfizer, Belgium



ICH Q 9 Training Course

19-20 October 2016, Berlin, Germany

ICH Q10 Training Course

20-21 October 2016, Berlin, Germany



Save money and book both courses for € 990,- each!

ICH Q9 Training Course 19-20 October 2016, Berlin, Germany

US (FDA) and in Japan. The ICH Q9 training course in hand deals with the practical implementation of the requirements . Individual examples help to show the application in the follow ing GMP areas: Validation Change Control/Change Management Auditing/Inspections Quality Systems As a complement to the lectures, the closing workshop offers the opportunity to practise Quality Risk Management techniques with a case study . Target Audience This event has been designed for quality assurance personnel. It also addresses staff from other departments, like e.g. production, engineering, quality control, and regulatory affairs. Programme ICH Q 9 Quality Risk Management Basic requirements Comparison to ISO 14971 Practical Examples How to Realise Quality Risk Management in a GMP Environment How to Apply Quality Risk Management in Validation What does the FDA expect for batch conformance prior to, and post, product approval What does ICH Q 9 man with respect to quality risk management in validation What does ICH Q9 many with respect to quality risk management in validation What does ICH Q9 many management in validation What does ICH Q9 many with respect to quality risk management in validation What does ICH Q9 many with respect to quality risk management in validation What does ICH Q9 many with respect to quality risk management in validation What does ICH Q9 many with respect to quality risk management in validation What does ICH Q9 many with respect to quality risk management in validation What does ICH Q9 many with respect to quality risk management in validation						
As a complement to the lectures, the closing workshop offers the opportunity to practise Quality Risk Management techniques with a case study. Target Audience This event has been designed for quality assurance personnel. It also addresses staff from other departments, like e.g. production, engineering, quality control, and regulatory affairs. Programme Easic requirements ICH Q 9 Quality Risk Basic requirements Comparison to ISO 14971 Practical Examples How to Realise Quality Risk An overview of the diverse techniques (HACCP, FTA etc.) Access benefit of some tools Access benefit of some tools Environment Understand why the use of risk management in process validation is now expected What does the FDA expect for batch conformance prior to, and post, product approad) What does ICH Q9 mean with respect to quality risk management in validation Design of an Event Handling System based on a Quality Sisk Management principles The quality system Risk management in a Phyroach The quality system Risk management principles Events (e. g. deviations, complaints etc.) Basic capuity Risk The quality system Risk management principles Events (e. g. deviations, complaints etc.) Risk management principles Events (e. g. deviations, complaints etc.) Risk Management in a Pharmaceutical Company <td>Objectives</td> <td> 2005 (Step 5). Consequently, this guideline has been implemented in the EU, the US (FDA) and in Japan. The ICH Q9 training course in hand deals with the practical implementation of the requirements. Individual examples help to show the application in the following GMP areas: Validation Change Control/Change Management Auditing/Inspections </td>	Objectives	 2005 (Step 5). Consequently, this guideline has been implemented in the EU, the US (FDA) and in Japan. The ICH Q9 training course in hand deals with the practical implementation of the requirements. Individual examples help to show the application in the following GMP areas: Validation Change Control/Change Management Auditing/Inspections 				
staff from other departments, like e.g. production, engineering, quality control, and regulatory affairs. Programme ICH Q 9 Quality Risk Management Basic requirements How to Realise Quality Risk Management in a GMP Environment An overview of the diverse techniques (HACCP, FTA etc.) How to Apply Quality Risk Management in Validation An overview of the diverse techniques (HACCP, FTA etc.) How to Apply Quality Risk Management in Validation Understand why the use of risk management in process validation is now expected What does the FDA expect for batch conformance prior to, and post, product approval What does the FDA expect for batch conformance prior to, and post, product approval Design of an Event Handling System based on a Quality System and Quality Risk Management Approach The quality risk management approach versus the traditional 3 batch validation approach? How to implement Quality Risk Management in a Pharmaceutical Company The quality system How to implement Quality Risk Management in a Pharmaceutical Company The risk-based approach and its impact on key GMP processes (GAMP*5, FDA Guidance on Process Validation, etc.) How to Make a Risk- based Audit Schedule Understand how to assess risk between different operations identify priorities for the audit i. Learn how to use a point system to assign audit priorities based on risk		As a complement to the lectures, the closing workshop offers the opportunity to				
ICH Q 9 Quality Risk Basic requirements Management Comparison to ISO 14971 Practical Examples An overview of the diverse techniques (HACCP, FTA etc.) How to Realise Quality Risk An overview of the diverse techniques (HACCP, FTA etc.) How to Apply Quality Risk Understand why the use of risk management in process validation is now expected How to Apply Quality Risk Understand why the use of risk management in process validation is now expected What does the FDA expect for batch conformance prior to, and post, product approval What does the FDA expect for batch conformance prior to, and post, product approval What does the PDA expect for batch conformance prior to validation will result in le ongoing process support during production Learn why the quality risk management approach to validation will result in le ongoing process support during production Design of an Event Handling The quality system Risk management approach Risk management application Outputs The risk-based approach and its impact on key GMP processes (GAMP*5, FDA Guidance on Process Validation, etc) How to Make a Risk-based Audit Schedule Understand how to assess risk between different operations Identify priorities for the audit Understand how to use a point system to assign audit priorities based on risk	Target Audience	staff from other departments, like e.g. production, engineering, quality control,				
ManagementComparison to ISO 14971 Practical ExamplesHow to Realise Quality Risk Management in a GMP EnvironmentAn overview of the diverse techniques (HACCP, FTA etc.) Access benefit of some tools Examples from the production of drug (medicinal) products and APIsHow to Apply Quality Risk Management in ValidationUnderstand why the use of risk management in process validation is now expectedWhat does the FDA expect for batch conformance prior to, and post, product approvalWhat is the benefit of using the risk management approach versus the traditional 3 batch validation approach?Design of an Event Handling System based on a Quality System and Quality Risk Management ApproachThe quality system Risk management principles Events (e. g. deviations, complaints etc.) Risk Management QualityHow to implement Quality Risk Management up Pharmaceutical CompanyThe risk-based approach and its impact on key GMP processes (GAMP*5, FDA Guidance on Process Validation, etc)How to Make a Risk- based Audit ScheduleUnderstand how to assess risk between different operations I (End Q9 in the context of ICH Q8 and ICH Q10 The implement and shop floor level (tools and experiences)	Programme					
 Management in a GMP Environment Access benefit of some tools Examples from the production of drug (medicinal) products and APIs How to Apply Quality Risk Management in Validation Understand why the use of risk management in process validation is now expected What does the FDA expect for batch conformance prior to, and post, product approval What is the benefit of using the risk management approach versus the traditional 3 batch validation approach? What does ICH Q9 mean with respect to quality risk management in validation Learn why the quality risk management approach to validation will result in le ongoing process support during production Design of an Event Handling System based on a Quality The quality system Risk management principles Events (e. g. deviations, complaints etc.) Risk management application Outputs The risk-based approach and its impact on key GMP processes (GAMP*5, FDA Guidance on Process Validation, etc) ICH Q9 in the context of ICH Q8 and ICH Q10 The risplement and shop floor level (tools and experiences) How to Make a Risk- based Audit Schedule Understand how to assess risk between different operations I dentify priorities for the audit Learn how to use a point system to assign audit priorities based on risk 	•	Comparison to ISO 14971				
Management in ValidationexpectedWhat does the FDA expect for batch conformance prior to, and post, product approvalWhat is the benefit of using the risk management approach versus the traditional 3 batch validation approach?What is the benefit of using the risk management approach versus the traditional 3 batch validation approach?Design of an Event Handling System based on a Quality System and Quality Risk Management ApproachThe quality systemRisk management principles Events (e. g. deviations, complaints etc.)Risk management application OutputsHow to implement Quality Risk Management in a Pharmaceutical CompanyThe risk-based approach and its impact on key GMP processes (GAMP*5, FDA Guidance on Process Validation, etc)How to Make a Risk- based Audit ScheduleUnderstand how to assess risk between different operations Identify priorities for the audit Learn how to use a point system to assign audit priorities based on risk	Management in a GMP	Access benefit of some tools				
 System based on a Quality Risk management principles Events (e. g. deviations, complaints etc.) Risk management application Outputs How to implement Quality Risk management application Outputs The risk-based approach and its impact on key GMP processes (GAMP®5, FDA Guidance on Process Validation, etc) ICH Q9 in the context of ICH Q8 and ICH Q10 The implementation of "quality risk management thinking and doing" on management and shop floor level (tools and experiences) How to Make a Risk-based Audit Schedule Understand how to assess risk between different operations Identify priorities for the audit Learn how to use a point system to assign audit priorities based on risk 		 expected What does the FDA expect for batch conformance prior to, and post, product approval What is the benefit of using the risk management approach versus the traditional 3 batch validation approach? What does ICH Q9 mean with respect to quality risk management in validation Learn why the quality risk management approach to validation will result in less 				
 Risk Management in a Pharmaceutical Company FDA Guidance on Process Validation, etc) ICH Q9 in the context of ICH Q8 and ICH Q10 The implementation of "quality risk management thinking and doing" on management and shop floor level (tools and experiences) How to Make a Risk- based Audit Schedule Understand how to assess risk between different operations Identify priorities for the audit Learn how to use a point system to assign audit priorities based on risk 	System based on a Quality System and Quality Risk	 Risk management principles Events (e. g. deviations, complaints etc.) Risk management application 				
 based Audit Schedule Identify priorities for the audit Learn how to use a point system to assign audit priorities based on risk 	Risk Management in a	 FDA Guidance on Process Validation, etc) ICH Q9 in the context of ICH Q8 and ICH Q10 The implementation of "quality risk management thinking and doing" on 				
		 Identify priorities for the audit Learn how to use a point system to assign audit priorities based on risk 				

Workshop Quality Risk Management in Practice

Learn how to **create an audit schedule by looking at the various risk categories** associated with the various operational activities within the differing units. This workshop will help you look across the different units from production operations, vendors, third-parties and laboratories, rank them by risk and then apply this to a template to create an audit schedule covering the next 3 years.

After the workshop you will be able to use or adapt the template to conduct a similar risk profile for your own facilities and third-party operations



Speakers



Richard M. Bonner, formerly with Eli Lilly, United Kingdom

Mr Bonner is currently located in the UK and works as a consultant to the Pharmaceutical Industry. Previous to his current role he was a Senior Quality Adviser for Eli Lilly and Company. He had 31 years experience within the pharmaceutical industry working in production, technical services and both Quality Control and Quality Assurance functions. He has been involved in multiple inspections from

the MHRA, FDA and other authorities. Mr Bonner is a Qualified Person in Europe and Chairman of the European Compliance Academy.



Dr Helene Zuurmond, Pfizer, Belgium

Dr Helene Zuurmond studied Chemistry at Leiden University in the Netherlands. After working at a Pfizer site in Italy in the registration compliance and quality systems area, she is now working in the Global Quality Organisation within the same company, where she is responsible for design and implementation of compliant and efficient quality systems at the Pfizer manufacturing sites



Dr Heinrich Prinz, Apceth GmbH, Germany

Dr Prinz worked with Boehringer Mannheim before he joined Biotest where he was Head of Quality Assurance, responsible for both the pharmaceutical and the medical device division. Since 2003 he works as a freelance consultant and part of his time he is the Senior Supervisor 'Production and Quality Assurance' at Apceth, a biotech company.



Dr Thomas Schneppe, Bayer Pharma AG, Berlin, Germany

Dr Thomas Schneppe worked for Klöckner Pentapack Contract Manufacturing, Asche AG and Schering AG. Since 2006 he is Head of the Department Integrated Quality Management Training at Bayer Pharma AG.

ICH Q 10 Training Course 20-21 October 2016, Berlin, Germany

Objectives	The International Conference on Harmonisation has published the Guidance ICH Q10 Pharmaceutical Quality Systems in June 2008. This Guideline has been trans- ferred to European, US and Japanese regulation. Thus, all companies in these re- gions have to implement the key requirements of ICH Q10. However, the US FDA is still using their own Guidance for Industry (Quality System Approach to Pharma- ceutical cGMP).				
	The implementation of these requirements have caused a number of questions. Among others ISO elements like continual improvement are new in the pharma- ceutical industry. This training course has been developed to discuss the require- ments and how they can be implemented in pharmaceutical industry.				
Target Group	This event has been designed for quality assurance personnel. It also addresses staff from other departments, like e.g. production, engineering, quality control, and regulatory affairs.				
	In addition the topics will be further discussed in interactive Workshops.				
Programme					
Introduction to ICH Q10	 What are the key elements of ICH Q10? Comparison with the FDA Guidance for Industry How to comply with the Guidelines 				
Continual Improvement (Part 1)	 Process Monitoring Key Performance Indicators (KPIs) Process Performance and Capability (link to Q8, Q9 and Process Validation) 				
Continual Improvement (Part 2)	 CAPA Management as a tool for Continual Improvement Change Management Trending Annual Reviews 				
Monitoring Quality Process Performance and Quality System	 The Senior Management's responsibility How to perform Quality Management Reviews Key Elements of a Review System 				
Responsibility of Senior Management	 How to involve the management Management Review Practical Examples 				
Management of Outsourced Activities and Purchased Materials	 How to choose, qualify and monitor Suppliers and Providers Supplier Qualification as Part of the Quality System Change of Ownership Monitoring of the performance Implementation of QMS - some milestones 				

All presentations will also include interactive Workshops!

Speakers



Dr Heinrich Prinz, Apceth GmbH , Germany

Dr Prinz worked with Boehringer Mannheim before he joined Biotest where he was Head of Quality Assurance, responsible for both the pharmaceutical and the medical device division. Since 2003 he works as a freelance consultant. In addition, he is the Senior Supervisor 'Production and Quality Assurance' at Apceth,

a biotech company.



Dr Bernd Renger, Immediate Past Chairman of the European QP Association; **Renger Consulting, Germany**

Dr Bernd Renger is a member of the European Compliance Academy (ECA) Advisory Board and Immediate Past Chairman of the European QP Association. Since 2011, he is running his own consultancy business. Before that he was VP of Quality Control at Vet-

ter Pharma-Fertigung. He started his career 1977 at Hoechst AG as a research and development chemist. Since then, he has held several positions at Mundipharma, Byk Gulden (now Takeda) and Baxter BioScience in Vienna.



Dr Thomas Schneppe,

Bayer Pharma AG, Berlin, Germany Dr Thomas Schneppe worked for Klöckner Pentapack Contract Manufacturing, Asche AG and Schering AG. Since 2006 he is Head of the Department Integrated Quality Management Training at Bayer Pharma AG.

Quality Management Manual of a fictive Company on CD-ROM free of charge for all participants of the ICH Q10 course



Manual

PLUS

The Quality Management Manual of the fictive company "Example" does not only take into consideration the quality assurance system (QA System) as required by the GMP regulation but also the requirements of the international standards EN ISO 9001: 2000 on Quality Management Systems and EN ISO 13485: 2003 "Quality Management Systems - Medical Devices - Requirements for Regulatory Purposes". The Quality Manual was developed by a task force of the German Medicines Manufacturers Association.

The content is structured according to ISO 9001. In the appendix of the publication you will find exemplary job descriptions, e.g. for the Qualified Person, Head of Production and Head of Quality Control. Further examples include forms for the review by the management and a process flow chart.

ICH Q10 versus ISO 9001-2015 Matrix

As part of the conference binder the participants will also receive a matrix which compares the ICH Q10 Guideline and the international standard on quality management ISO 9001. This matrix is helpful to identify areas that are not covered in one of the two documents.

Social Event



On Wednesday evening you are cordially invited to a social event. This is an excellent opportunity to share your own views and experiences with colleagues from other companies in a relaxed and casual atmosphere.

Join us for a guided city tour and a dinner in the heart of Berlin

Easy Registration

Reservation Form: P CONCEPT HEIDELBERG P.O. Box 10 17 64

69007 Heidelberg, Germany

ICH Q9 Training Course

Wednesday, 19 October 2016, 10.00 - 17:45 h (Registration and coffee 09.30 - 10.00 h) Thursday, 20 October 2016, 09.00-12.15 h

Conference fees (per delegate plus VAT)

ECA Members € 1.090 APIC Members € 1,190 Non-ECA Members € 1,290 EU GMP Inspectorates € 645 The conference fee is payable in advance after receipt of invoice and includes conference documentation, lunch and dinner (Social Event) on the first day, and all refreshments. VAT is reclaimable.

ICH Q10 Training Course

Thursday, 20 October 2016, 13.30 - 17.45 h (Registration and coffee 13.00 - 13.30 h) Friday, 21 October 2016, 09.00 - 16.00 h

Venue of both courses

Steigenberger Hotel Berlin Los-Angeles-Platz 1 10789 Berlin Phone +49 (0)30 212 7 - 0 +49 (0)30 212 7-799 Fax

Reservation Form: + 49 6221 84 44 34

ECA Members € 1,090

APIC Members € 1,190

Non-ECA Members € 1,290

EU GMP Inspectorates € 645

e-mail: (a)info@concept-heidelberg.de

Internet: 伯 www.gmp-compliance.org

Registration

Via attached reservation form, by e-mail or by fax message. Or you register online at www.gmp-compliance.org.

Conference language

The official conference language will be English. **Organisation and Contact** ECA has entrusted Concept Heidelberg with the

Save money and book both courses for € 990,- <u>EACH</u>!

all refreshments. VAT is reclaimable.

Conference fees (per delegate plus VAT)

The conference fee is payable in advance after

documentation, lunch on the second day and

receipt of invoice and includes conference

If you book the "ICH Q9 Training Course" AND the "ICH Q10 Training Course" simultaneously, the fee for EACH conference reduces as follows: ECA Members € 891 APIC Members € 940 Non-ECA Members € 990 EU GMP Inspectorates € 495

Accommodation

CONCEPT has reserved a limited number of rooms in the conference Hotel. You will receive a room reservation form when you have registered for the course. Reservation should be made directly with the hotel. Early reservation is recommended.

organisation of this event.

CONCEPT HEIDELBERG P.O. Box 10 17 64

69007 Heidelberg, Germany Phone +49 (0) 62 21/84 44-0 Fax +49 (0) 62 21/84 44 34 E-mail: info@concept-heidelberg.de www.concept-heidelberg.de

For questions regarding content:

Mr Oliver Schmidt, Operations Director, at +49 (0) 62 21 / 84 44 23, e-mail: schmidt@concept-heidelberg.de

For questions regarding reservation, hotel, organisation etc.:

Ms Susanne Ludwig, Organisation Manager, at +49 (0) 62 21 / 84 44 44 e-mail: ludwig@concept-heidelberg.de

If the bill-to-address deviates from the specification to the right, please fill out	<i>Registration form (ple</i> here:	ase complete in full)	
	□ ICH Q 9 Training C 19-20 October 201		
	□ ICH Q 10 Training 20-21 October 2010		
	Mr 🛛 Ms	Title	
	First name, surname		
	Company		
CONCEPT HEIDELBERG P.O. Box 10 17 64	Department		
Fax +49 (0) 6221/84 44 34	Important: Please indicate	your company's VAT ID Number F	Purchase Order No. (if applicable)
69007 Heidelberg Germany	Street / P.O. Box		
	City	Zip Code	Country
	Phone / Fax		
	E-mail (please fill in)		
It you have to cancel entirely we must charge r	CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to ancel an event. If the event must be cancelled, registrants will be notified as soon as possible and will receive a full efund of fees paid. CONCEPT HEIDELBERGwill not be esponsible for discount affere negatives or other costs	If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registra- tion fee even if you have not made the navment vet	Privacy Policy: By registering for this event. I accept the processing of my Personal Data. Concept Heidelberg will use my data for the processing of this order, for which I hereby declare to agree that my personal data is stored and processed. Concept Heidelberg will only send me information in relation with this order or similar ones.

tollowing processing tees: Cancellation until 2 weeks prior to the conference 10 %, until 1 weeks prior to the conference 50 % within 1 week prior to the conference 100 %.

responsible for discount antare penames or other costs incurred due to a cancellation. **Terms of payment:** Payable without deductions within 10 days after receipt of invoice. **Important:** This is a binding registration and above fees are due in case of cancellation or non-appearance.

Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed)! (As of January 2012).

me momentum in relation with this order or similar ones. My personal data will not be disclosed to third parties (see also the privacy policy at http://www.gmp-compliance.org/ eca_privacy.html). I note that I can ask for the modification, correction or deletion of my data at any time via the contact form on this website.